
[Federal Register: June 24, 2010 (Volume 75, Number 121)]
[Notices]               
[Page 36101-36102]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jn10-57]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0001]

 
Dermatologic and Ophthalmic Drugs Advisory Committee; 
Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Dermatologic and Ophthalmic Drugs Advisory 
Committee scheduled for June 28, 2010, is cancelled. This meeting was 
announced in the Federal Register of May 11, 2010 (75 FR 26264). The 
meeting was to discuss new drug application (NDA) 22-340, voclosporin 
10-milligram capsules, by Lux Biosciences Inc. This meeting has been 
cancelled to allow time for the resolution of several outstanding 
issues. The agency intends to continue evaluating NDA 22-340 and, as 
needed, may schedule an advisory committee meeting in the future.

FOR FURTHER INFORMATION CONTACT: Yvette Waples, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, e-mail: Yvette.Waples@fda.hhs.gov, or FDA 
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), code 3014512534. Please call the Information 
Line for up-to-date information on this meeting.


[[Page 36102]]


    Dated: June 18, 2010.
Thinh Nguyen,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-15352 Filed 6-23-10; 8:45 am]
BILLING CODE 4160-01-S

